Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) EBITDA (2020 - 2025)

Historic EBITDA for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $2.6 million.

  • Mirum Pharmaceuticals' EBITDA rose 12052.19% to $2.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.8 million, marking a year-over-year increase of 5645.36%. This contributed to the annual value of -$87.6 million for FY2024, which is 1974.09% up from last year.
  • Latest data reveals that Mirum Pharmaceuticals reported EBITDA of $2.6 million as of Q3 2025, which was up 12052.19% from -$5.0 million recorded in Q2 2025.
  • In the past 5 years, Mirum Pharmaceuticals' EBITDA ranged from a high of $2.6 million in Q3 2025 and a low of -$47.6 million during Q1 2021
  • For the 5-year period, Mirum Pharmaceuticals' EBITDA averaged around -$27.3 million, with its median value being -$27.1 million (2023).
  • As far as peak fluctuations go, Mirum Pharmaceuticals' EBITDA tumbled by 11610.84% in 2021, and later skyrocketed by 12052.19% in 2025.
  • Quarter analysis of 5 years shows Mirum Pharmaceuticals' EBITDA stood at -$45.6 million in 2021, then increased by 25.04% to -$34.2 million in 2022, then grew by 4.61% to -$32.6 million in 2023, then increased by 25.67% to -$24.2 million in 2024, then skyrocketed by 110.75% to $2.6 million in 2025.
  • Its EBITDA stands at $2.6 million for Q3 2025, versus -$5.0 million for Q2 2025 and -$15.2 million for Q1 2025.